Pharmacologic Therapy of Type 2 Diabetes

Med Clin North Am. 2016 Jul;100(4):647-63. doi: 10.1016/j.mcna.2016.03.014.

Abstract

Type 2 diabetes (T2DM) is a common condition. Treatment of diabetes and related complications can be complex. In addition to lifestyle changes, medications play an important role in controlling patients' blood glucose levels and preventing complications. From an individual and societal standpoint, it is also an expensive disease. Medical spending attributed to diabetes per individual is significant. With appropriate therapy, patients can lead full, healthy lives with the disease, so making informed decisions regarding pharmacotherapy for T2DM is clearly of great importance.

Keywords: DPP-4 inhibitor; GLP-1 analog; Insulin; Metformin; SGLT-2 inhibitor; Sulfonylurea; Type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Aging
  • Blood Glucose
  • Body Weight
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
  • Drug Administration Routes
  • Glucagon-Like Peptide 1 / agonists
  • Glycated Hemoglobin
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / economics
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / therapeutic use
  • Metformin / therapeutic use
  • Renal Insufficiency / epidemiology
  • Sodium-Glucose Transporter 2 Inhibitors
  • Sulfonylurea Compounds / therapeutic use
  • Thiazolidinediones / therapeutic use

Substances

  • Blood Glucose
  • Dipeptidyl-Peptidase IV Inhibitors
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Sodium-Glucose Transporter 2 Inhibitors
  • Sulfonylurea Compounds
  • Thiazolidinediones
  • Glucagon-Like Peptide 1
  • Metformin